▎WuXiEdited by Kant Content Team

AbbVie recently announced positive results from its pivotal phase 3 trial, TEMPO-1. Analysis shows that its investigational small molecule therapy, tavapadon, as a fixed-dose monotherapy for early Parkinson's disease (PD) patients, met the primary endpoint with statistically significant improvement in the combined scores of parts 2 and 3 of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) compared to baseline.Another Phase 3 trial, TEMPO-2, is examining the effects of tavapadon as a flexible-dose monotherapy, with results expected to be announced by the end of 2024.

Parkinson's disease is the second most common neurodegenerative disease after Alzheimer's disease, with approximately 10 million PD patients worldwide.The main motor symptoms of PD are characterized by limb tremors at rest, rigidity, and impaired motor function, while non-motor symptoms include cognitive, emotional, and sleep disorders.The cause of PD is the death of dopamine-producing neurons in the substantia nigra of the patient.The current treatment methods for PD are levodopa or other dopamine agonists.

The TEMPO-1 trial evaluated the efficacy, safety, and tolerability of two fixed doses (5 mg and 15 mg, once daily) of tavapadon as a monotherapy for adult patients with early Parkinson's disease. The analysis showed that the trial met its primary endpoint.Compared with placebo, patients receiving two doses of tavapadon treatment had statistically significant reductions in the combined scores of MDS-UPDRS Part 2 and 3 at week 26 from baseline, indicating improvement in their condition (placebo group: +1.8; 5 mg group: -9.7; 15 mg group: -10.2; p-value <0.0001 for each dose compared with placebo).

In addition, the TEMPO-1 trial also met the key secondary endpoint, which was compared with the placebo group at week 26.Patients in both tavapadon dose groups showed statistically and clinically meaningful improvements in motor aspects of daily living experiences (MDS-UPDRS Part 2).

Tavapadon is an investigational selective D1/D5 receptor partial agonist currently being studied as a monotherapy and as an adjunctive therapy to levodopa (LD) for the treatment of patients with Parkinson's disease.Tavapadon is designed to selectively and optimally activate D1/D5 receptors, thereby providing patients with an appropriate balance of motor control, safety, and tolerability.By selectively activating D1/D5 dopamine receptors on the nigrostriatal pathway, tavapadon has the potential to provide an appropriate balance of dopamine signaling to improve motor control, while avoiding overstimulation of D2/D3, which is considered to be the cause of many side effects associated with current dopamine agonists.In addition, as a partial agonist with a half-life of 24 hours, tavapadon can be taken once daily, thereby avoiding dyskinesia caused by excessive activation of dopamine receptors.

In December last year, AbbVie and Cerevel reachedFinal AgreementAbbVie Acquires Cerevel for Approximately $8.7 Billion, Gaining Access to Its Extensive Neuroscience Pipeline. In the press release, AbbVie noted that tavapadon’s efficacy and safety/tolerability profile enables it to benefit patients with early-stage Parkinson's disease, complementing AbbVie’s existing pipeline of symptomatic treatments for advanced Parkinson's disease.

▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.

References:

[1] AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease. Retrieved September 26, 2024 from https://news.abbvie.com/2024-09-26-AbbVie-Announces-Positive-Topline-Results-from-Phase-3-TEMPO-1-Trial-Evaluating-Tavapadon-as-a-Monotherapy-for-Parkinsons-Disease

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article. This article is not a recommendation for treatment plans. For guidance on obtaining treatment plans, please visit a正规 hospital.

Copyright Statement: This article is from the WuXi AppTec content team. Individuals are welcome to share it on their social media platforms, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the "WuXi AppTec" WeChat Official Account to obtain reprint guidelines.